Tracking Urinary Biomarkers Over Two Weeks in Preterm Very Low Birth Weight Infants Studying Effects of Clinical Factors and Treatments on Kidney Health

What this Trial Is About

Researchers are studying the patterns of specific urinary biomarkers in the first two weeks of life in premature and very low birth weight infants. The study aims to understand how factors like patent ductus arteriosus, prenatal blood flow changes, and drug treatments affect these biomarkers. It also seeks to evaluate how well these biomarkers predict kidney damage in this vulnerable group and to establish possible cut-off values for clinical use. The study does not involve any drugs or treatments but focuses on observing and measuring biomarkers such as Cystatin C, epithelial growth factor, NGAL, beta-2 Microglobulin, Osteopontin, kidney injury molecule 1, and modulin in urine samples. These biomarkers can be collected noninvasively and repeatedly without requiring blood draws. The goal is to improve early detection and monitoring of kidney function in preterm infants, who are at risk of acute kidney injury due to various clinical factors. Participants will be monitored in the neonatal intensive care unit after birth, with urine samples collected during the first two weeks of life. Researchers will analyze these samples alongside clinical information, including prenatal Doppler flow and drug exposures. The main outcome is the timing and pattern of these urinary biomarkers, tracked over an average of two years. This long-term observation helps assess how early kidney markers relate to later kidney health and potential damage in premature infants.

Evaluation of Urinary Biomarkers Trend in Preterm Very Low Birth Weight Infants